Table 2.
Patient characteristics of the tumor tissue proteome/TIF studies.
| First Author, Year, Country, [Ref] | Platform | Study Samples (Tumor Tissue) | Study Samples (Blood) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sample Size (N) Cases NM |
% Late Stage (III/IV) CRC |
Mean Age (Range/±SD) CRC |
% Males CRC |
Sample Size (N) CRC Cn |
% Late Stage (III/IV) CRC |
Mean Age (Range/±SD) CRC Cn |
% Males CRC Cn |
|||
| Combination Marker Studies | ||||||||||
| Broll, 2001, Germany [56] |
SPM | 38 paired CRC & NC | - | - | - | 122 65 |
44 | 68.3 (32–92) 66.4 (27–89) |
49 48 |
|
| Alberthsen, 2006, Denmark [60] | SELDI-TOF MS | 32 CRC tumors | 50 | - | 63 | 119 34 |
49 | - (50–80) |
56 53 |
|
| Yoneda, 2009, Japan [41] | MA, IHC | - | - | - | - | 159 40 |
42 | (38–90) (29–85) |
67 53 |
|
| Kijanka, 2010, Ireland [62] | IHC | 43 CRC 19 NM |
- | - | - | 43 40 |
- | - | - | |
| Xie, 2010, China [27] | GeMS, TiMA | 93 paired CRC & NC | 3 | 66.05 ± 13.89 | 53 | 42 42 |
- | - | - | |
| Hamelin, 2011, France [61] | MALDI, IHC | 20 paired CRC & NC | 70 | - | 50 | 112 90 |
50 | 70 (± 11) 58 (± 4) |
54 60 |
|
| Kuo, 2011, Taiwan [39] | IHC | 104 paired CRC & NM | 92 | - | 47 | 59 52 |
58 | - | 58 - |
|
| Matsubara, 2011, Japan [42] | IHC, RPPM | 20 tissues | - | - | - | 26 87 |
35 | 63.0 (±12.0) 43.0 (±16.0) |
50 64 |
|
| Wang, 2013, China [25] | MALDI, IHC | 248 CRC 75 NM |
- | - | - | 143 85 |
46 | 54.7 (±1.02) 52.5 (±1.19) |
58 51 |
|
| Jiang, 2014, China [23] | IHC | 98 CRC 30 NC |
61 | (28–88) | 62 | 182 101 |
- | 61 (23–86) (21–62) |
52 45 |
|
| Surinova, 2015, Germany, CR [58] | LC/MS-MS | 16 paired CRC & NC | 25 | 62.3 ± 9.5 | 81 | 202 67 |
50 | 67 (59–74.8) 49 (52–65) |
56 76 |
|
| Xue, 2014, China [29] | WB | 190 paired CC & NC | 45 | 66 (22–95) | 43 | 120 40 |
37 | 66.8 (26–93) 39.2 (23–59) |
41 - |
|
| Wang Y, 2016, China [32] | LC/MS-MS | TIF 16 AOM-DSS mice | - | - | - | 16 16 |
56 | (35–67) | 56 | |
| Xie, 2016, China[34] | LC/MS-MS | TIF ApcMin/+ & WT mice | - | - | - | 30 30 |
- | (31–70) (31–70) |
60 57 |
|
| Individual Marker Studies | ||||||||||
| Roessler, 2005, Germany [57] | SDS | 18 paired CRC & NM | 28 | 73.3 (±9.7) | 61 | 109 317 |
40 | - (12–89) |
- | |
| Kim, 2009, Korea [47] | 2-D DIGE, MS, IHC | 6 paired CRC & NM | 33 | 53.5 (±11.4) | 50 | 77 21 |
52 | - | ||
| Ji, 2010, Korea [45] | MA, WB, IHC | 66 paired CRC & NM | - | - | - | 100 78 |
49 |
- | 61 - |
|
| Han, 2011, China [21] | LC/MS-MS | 28 paired CRC & NM | 61 | 62.2 (±14.3) | 57 | 70 70 |
- | - | - | |
| Fijneman, 2012, The Netherlands [63] | GeLC/MS-MS | TIFFabplCre;apc15lox/+C57Bl/6 mice | - | - | - | 8 36 |
63 | 71.8 (±6.4) 60.2 (±13.8) |
50 42 |
|
| Hosono, 2012, Japan [44] | IHC | 62 adenoma | - | - | - | 62 A 34 |
- | 67.7 (±8.2) 67.6 (±15.9) |
63 59 |
|
| Yao, 2012, China [30] | IHC | 88 CRC 16 NM |
41 | (35–88) | 57 | 122 79 |
- | - | - - |
|
| Ji, 2013, China [22] | IHC, LC/MS-MS | 294 CRC | 71 | 59.55 ± 12.34 | 55 | 405 84 |
48 | - | 55 56 |
|
| Niewiarowska, 2014, Poland [64] | IHC | 38 CRC tissues | - | - | - | 43 24 |
88 | 67.1 (±1.89) 55.7 (±7.3) |
63 | |
| Sole, 2014, Spain [55] | LC/MS-MS | 70 CRC 34 NM |
0 | 62.5 (50–69) | 23 | 80 77 |
55 | 67 (34–89) 66 (22–83) |
65 51 |
|
Note: Age is in years; -: means not specified by the study; A: The study population consisted of Adenoma cases only. Abbreviations: CRC: Colorectal Cancer; Cn: Controls; 2-D DIGE: 2D-differential gel electrophoresis; GeLC/MS-MS: Nano-liquid chromatography-tandem mass spectrometry; GeMS: In-gel digestion coupled with mass spectrometric analysis; IHC: Immunohistochemistry; LC/MS-MS: Liquid chromatography-tandem mass spectrometry; MA: Microarray; MALDI: Matrix-assisted laser desorption/ionization; NC: Normal colonic tissue; NN: Nonneoplastic; NM: Normal mucosa; RPPM: Reverse phase protein microarray; SDS: SDS PAGE or sodium dodecyl sulphate-polyacrylamide gel electrophoresis; SELDI-TOF MS: surface-enhanced laser desorption ionization time of flight mass spectrometry; SPM: Spectrophotometrically with protein assay; TiMA: Tissue microarray; TIF: Tissue interstitial fluid; WB: Western Blot.